$430 Million is the total value of New Leaf Venture Partners, L.L.C.'s 18 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 5.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARVN | ARVINAS INC | $150,909,000 | -22.2% | 2,283,048 | 0.0% | 35.12% | -21.6% | |
| HARP | Buy | HARPOON THERAPEUTICS INC | $66,038,000 | +36.1% | 3,156,699 | +8.1% | 15.37% | +37.1% |
| DCPH | DECIPHERA PHARMACEUTICALS INC | $54,237,000 | -21.4% | 1,209,571 | 0.0% | 12.62% | -20.9% | |
| EWTX | New | EDGEWISE THERAPEUTICS INC | $50,494,000 | – | 1,553,661 | +100.0% | 11.75% | – |
| PASG | PASSAGE BIO | $43,664,000 | -31.6% | 2,497,922 | 0.0% | 10.16% | -31.1% | |
| CMRX | Sell | CHIMERIX INC | $11,805,000 | +81.0% | 1,224,600 | -9.3% | 2.75% | +82.3% |
| APTX | APTINYX INC | $9,870,000 | -13.3% | 3,290,079 | 0.0% | 2.30% | -12.7% | |
| SRRA | SIERRA ONCOLOGY INC | $7,058,000 | +7.5% | 409,611 | 0.0% | 1.64% | +8.3% | |
| ALEC | ALECTOR INC | $6,839,000 | +33.1% | 339,569 | 0.0% | 1.59% | +34.1% | |
| ARAV | ARAVIVE INC | $6,237,000 | +16.8% | 946,423 | 0.0% | 1.45% | +17.8% | |
| COGT | Buy | COGENT BIOSCIENCES INC. | $4,403,000 | -19.9% | 501,530 | +2.5% | 1.02% | -19.3% |
| AVRO | AVROBIO INC | $4,004,000 | -9.0% | 315,550 | 0.0% | 0.93% | -8.3% | |
| CHMA | CHIASMA INC | $3,555,000 | -28.0% | 1,135,700 | 0.0% | 0.83% | -27.5% | |
| OBSV | OBSEVA SA | $2,927,000 | +56.3% | 900,501 | 0.0% | 0.68% | +57.3% | |
| XFOR | X4 PHARMACEUTICALS INC | $2,884,000 | +33.9% | 335,000 | 0.0% | 0.67% | +34.7% | |
| CRNX | CRINETICS PHARMACEUTICALS INC | $2,154,000 | +8.2% | 141,000 | 0.0% | 0.50% | +8.9% | |
| ITRM | ITERUM THERAPEUTICS PLC | $2,053,000 | +42.6% | 1,456,303 | 0.0% | 0.48% | +43.5% | |
| PDSB | PDS BIOTECHNOLOGY CORP | $533,000 | +112.4% | 117,242 | 0.0% | 0.12% | +113.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DECIPHERA THERAPEUTICS INC | 25 | Q3 2023 | 44.4% |
| CHIMERIX INC | 25 | Q1 2023 | 20.9% |
| SIERRA ONCOLOGY INC | 22 | Q2 2022 | 14.9% |
| ARVINAS INC | 21 | Q3 2023 | 44.8% |
| CRINETICS PHARMACEUTICALS INC | 21 | Q3 2023 | 11.4% |
| OBSEVA SA | 20 | Q4 2021 | 8.5% |
| AVROBIO INC | 20 | Q1 2023 | 1.7% |
| HARPOON THERAPEUTICS INC | 19 | Q3 2023 | 20.0% |
| ALECTOR INC | 19 | Q3 2023 | 4.6% |
| ITERUM THERAPEUTICS PLC | 18 | Q3 2022 | 3.8% |
View New Leaf Venture Partners, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-06 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-09 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
View New Leaf Venture Partners, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.